MK-5442 in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated With an Oral Bisphosphonate (MK-5442-012)

Exclusion Criteria

• •Obesity (ie, weight greater than 250 pounds) that prohibits the use of dual-emission X-ray absorptiometry (DXA)
• •Received intravenous (IV) bisphosphonates, fluoride treatment at a dose \>1 mg/day for more than 2 weeks, strontium, growth hormone, a cathepsin K (CTSK) inhibitor, or a receptor activator of nuclear factor kappa-B ligand (RANKL) inhibitor at any time in the past
• •Use of oral bisphosphonates other than alendronate in the last 12 months, parathyroid hormone (PTH) in the last 24 months, cyclosporin for more than 2 weeks in the last 6 months, heparin in the last 2 weeks, or anabolic steroids or glucocorticoids for more than 2 weeks in the past 6 months
• •Use of estrogen with or without progestin or a selective estrogen receptor modulator (SERM) in the last 6 months or calcitonin in the last 30 days
• •Has used pioglitazone hydrochloride or rosiglitazone hydrochloride in the last 6 months
• •Taking more than 10,000 International Units (IU) vitamin A daily or more than 5,000 IU vitamin D daily
• •Has had a total thyroidectomy
• •History of Paget's disease
• •Has human immunodeficiency virus (HIV)
• •History of cancer in the last 5 years, except certain skin or cervical cancers
• •History of major upper gastrointestinal (GI) mucosal erosive disease
• •Unable to adhere to dosing instructions for alendronate in regard to fasting and positioning
• •Not ambulatory